Medicare AdvantageMarch 11, 2025
Medical Policies and Clinical Utilization Management Guidelines update
Effective April 12, 2025
The Medical Policies, Clinical Utilization Management (UM) Guidelines, and Third‑Party Criteria below were developed and/or revised with expanded rationales, medical necessity indications, or criteria. Some may involve changes to policy position statements that might result in services that previously were covered being found to be not medically necessary.
Please share this notice with other members of your practice and office staff.
To view a guideline, visit the Medical Policy and Clinical UM Guidelines website.
Medical Policies
The Medical Policy and Technology Assessment Committee (MPTAC) approved the following Medical Policies applicable to BMA. These medical policies take effect April 12, 2025.
Publish date | Medical Policy number | Medical Policy title | New or revised |
October 1, 2024 | DME.00011 | Electrical Stimulation as a Treatment for Pain and Other Conditions: Surface and Percutaneous Devices | Revised |
October 1, 2024 | DME.00052 | Brain Computer Interface Rehabilitation Devices | New |
October 1, 2024 | LAB.00026 | Systems Pathology and Multimodal Artificial Intelligence Testing for Cancerous and Precancerous Conditions | Revised |
October 1, 2024 | LAB.00051 | Per‑ and Polyfluoroalkyl Substances PFAS Testing | New |
October 1, 2024 | MED.00150 | Hepzato Kit™ (melphalan hepatic delivery system) | New |
October 1, 2024 | SURG.00032 | Patent Foramen Ovale and Left Atrial Appendage Closure Devices | Revised |
October 1, 2024 | TRANS.00023 | Hematopoietic Stem Cell Transplantation for Multiple Myeloma and Other Plasma Cell Dyscrasias | Revised |
Clinical UM Guidelines
The MPTAC approved the following Clinical UM Guidelines applicable to BMA. These guidelines were adopted by the medical operations committee for members. These guidelines take effect April 12, 2025.
Publish date | Clinical UM Guideline number | Clinical UM Guideline title | New or revised |
October 1, 2024 | CG‑LAB-33 | Carcinoembryonic Antigen Testing | New |
October 1, 2024 | CG‑LAB-35 | Cancer Antigen 19‑9 Testing | New |
October 1, 2024 | CG‑MED-39 | Bone Mineral Density Testing Measurement | Revised |
October 1, 2024 | CG‑SURG-01 | Colonoscopy | Revised |
October 1, 2024 | CG‑SURG-122 | Lingual Frenotomy for Ankyloglossia‑Related Feeding Difficulties | New |
October 1, 2024 | CG‑SURG-57 | Diagnostic Nasal Endoscopy | Revised |
Blue Medicare Advantage is the trade name of Group Retiree Health Solutions, Inc., an independent licensee of the Blue Cross Blue Shield Association.
PAIBC-CR-075678-24-CPN74692
To view this article online:
Or scan this QR code with your phone